# BioCardia, Inc.: overview BCDA · Nasdaq · CIK 925741 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bcda.md) · [Financials](/companies/bcda/financials.md) · [Filings](/companies/bcda/filings.md) · [Insiders](/companies/bcda/insiders.md) Latest reported revenue: [$0](/filings/0001437749-26-009587.md) for Q4 FY2025, three months to 2025-12-31, from the 10-K filed Mar 24, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax, accession 0001437749-26-009587). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [0.0](/filings/0001437749-25-034437.md) | [0.0 d](/filings/0001437749-26-009587.md) | [0.0](/filings/0001437749-25-016831.md) | [0.0](/filings/0001437749-25-032197.md) | [0.0](/filings/0001437749-25-034437.md) | [0.0 d](/filings/0001437749-26-009587.md) | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | [(0.59)](/filings/0001437749-26-017221.md) | [(0.40)](/filings/0001437749-26-027315.md) | not reported | not reported | [(0.21)](/filings/0001437749-26-017221.md) | not reported | | Free cash flow | $k | [(2,613) d](/filings/0001437749-25-034437.md) | [(2,434) d](/filings/0001437749-26-009587.md) | [(1,618)](/filings/0001437749-26-017221.md) | [(1,650) d](/filings/0001437749-26-027315.md) | [(1,672) d](/filings/0001437749-25-034437.md) | [(2,503) d](/filings/0001437749-26-009587.md) | [(1,662)](/filings/0001437749-26-017221.md) | [(1,735) d](/filings/0001437749-26-027315.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.0](/filings/0001437749-23-008312.md) | [1.4](/filings/0001437749-24-009587.md) | [0.5](/filings/0001437749-25-009397.md) | [0.1](/filings/0001437749-26-009587.md) | [0.0](/filings/0001437749-26-009587.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1244.3%)](/filings/0001437749-23-008312.md) | [(880.3%)](/filings/0001437749-24-009587.md) | [(2441.1%)](/filings/0001437749-25-009397.md) | [(13794.8%)](/filings/0001437749-26-009587.md) | not reported | | Net margin | % | [(1243.6%)](/filings/0001437749-23-008312.md) | [(880.7%)](/filings/0001437749-24-009587.md) | [(2425.8%)](/filings/0001437749-25-009397.md) | [(13700.0%)](/filings/0001437749-26-009587.md) | not reported | | Diluted EPS | $ per share | [(0.75)](/filings/0001437749-22-007544.md) | not reported | not reported | not reported | not reported | | Free cash flow | $m | [(10.5)](/filings/0001437749-23-008312.md) | [(10.6)](/filings/0001437749-24-009587.md) | [(10.0)](/filings/0001437749-25-009397.md) | [(7.9)](/filings/0001437749-26-009587.md) | [(7.4)](/filings/0001437749-26-009587.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bcda/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITIGROUP INC](/funds/831001.md) | 2026-06-30 | $493.0k | 397,594 | | New +397,594 | | [CM Management, LLC](/funds/1841857.md) | 2026-06-30 | $372.0k | 300,000 | | Added +170,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $154.5k | 124,591 | | Unchanged | | [Pingora Partners LLC](/funds/2011176.md) | 2026-06-30 | $149.3k | 120,382 | | Added +84,643 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $96.2k | 77,619 | | New +77,619 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $82.7k | 66,664 | | Reduced −27,623 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $82.2k | 66,270 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $48.1k | 38,809 | | Reduced −18 | | [BROWN ADVISORY INC](/funds/1345929.md) | 2026-06-30 | $44.1k | 35,538 | | Unchanged | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $29.0k | 23,383 | | Added +5,100 | ## Recent filings [All 939 filings](/companies/bcda/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 13:15 ET | [8-K](/filings/0001437749-26-032887.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032887 | | 2026-10-07 | 13:00 ET | [8-K](/filings/0001437749-26-032270.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-032270 | | 2026-10-01 | 13:15 ET | [8-K](/filings/0001437749-26-031665.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031665 | | 2026-09-23 | 13:15 ET | [8-K](/filings/0001437749-26-031011.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-031011 | | 2026-09-21 | 20:30 ET | [8-K](/filings/0001437749-26-030831.md) | 8.01 Other events | 0001437749-26-030831 | | 2026-09-10 | 12:30 ET | [8-K](/filings/0001437749-26-030023.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-26-030023 | | 2026-08-24 | 12:30 ET | [8-K](/filings/0001437749-26-028778.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-26-028778 | | 2026-08-21 | 20:34 ET | [8-K](/filings/0001437749-26-028744.md) | 3.01 Delisting notice | 0001437749-26-028744 | | 2026-08-12 | 20:27 ET | [8-K](/filings/0001437749-26-027332.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-26-027332 | | 2026-08-12 | 20:10 ET | [10-Q](/filings/0001437749-26-027315.md) | Quarterly report, period 2026-06-30 | 0001437749-26-027315 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001437749-26-009587.md), filed Mar 24, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 925741 - Tickers: BCDA - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.